Askgene Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ask-gene.com
Clinical Trials
7
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:6
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 3
1 (14.3%)ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 780
- Registration Number
- NCT06206733
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, China
A Study of ASKG712 in Patients With Diabetic Macular Edema
Phase 1
Not yet recruiting
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05940428
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT05867420
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.
Phase 1
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Drug: ASKB589 +CAPOX+Sintilimab
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT05632939
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of ASKG315 in Patients With Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- AskGene Pharma, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05554666
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Shandong cancer hospital, Jinan, Shandong, China
- Prev
- 1
- 2
- Next
News
No news found